Muckle-Wells syndrome effectively treated with canakinumab: is the recommended dosing schedule mandatory?
about
Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectivesAn expanding role for interleukin-1 blockade from gout to cancer.Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases.Treating inflammation by blocking interleukin-1 in humans.
P2860
Muckle-Wells syndrome effectively treated with canakinumab: is the recommended dosing schedule mandatory?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Muckle-Wells syndrome effectiv ...... ded dosing schedule mandatory?
@en
Muckle-Wells syndrome effectiv ...... ded dosing schedule mandatory?
@nl
type
label
Muckle-Wells syndrome effectiv ...... ded dosing schedule mandatory?
@en
Muckle-Wells syndrome effectiv ...... ded dosing schedule mandatory?
@nl
prefLabel
Muckle-Wells syndrome effectiv ...... ded dosing schedule mandatory?
@en
Muckle-Wells syndrome effectiv ...... ded dosing schedule mandatory?
@nl
P2093
P2860
P356
P1433
P1476
Muckle-Wells syndrome effectiv ...... ded dosing schedule mandatory?
@en
P2093
Peter Haeusermann
Peter Itin
Simon M Mueller
P2860
P304
P356
10.1159/000331580
P577
2011-09-29T00:00:00Z